CYTX : Analysis & Opinions

  1. Cytori Gets New Drug Patents: Expands to 90 (CYTX)

    Cytori Therapeutics continues to bolster its IP portfolio after receiving new drug patents in the US and Europe.
  2. Orphan Drug Status Spikes Cytori Stock 11% (CYTX)

    Cytori Therapeutics secured orphan drug status for its ECCS-50 drug to treat scleroderma.
  3. Cytori 3Q Loss of 26c/Share Misses Estimate (CYTX)

    Cytori posted a 3Q loss and revenue below analyst estimates.
  4. BARDA Increases Cytori Therapeutics’ Contract Option (CYTX)

    The renewed contract option indicates on-track progress of Cytori Cell Therapy, along with increased valuations.